Blue Crest Capital Management LTD Cyma Bay Therapeutics, Inc. Transaction History

Blue Crest Capital Management LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $59,739 - $266,357	-44,917 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $271,747 - $613,566	44,917 New	44,917 $322,000
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $168,686 - $302,809	-25,793 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$10.88 - $14.52 $280,627 - $374,514	25,793 New	25,793 $286,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $3.68 Million - $4.96 Million	-345,252 Closed	0 $0

Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $3.11 Million - $5.23 Million	345,252 New	345,252 $4.49 Million

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.